The latest price target for ADMA Biologics (NASDAQ: ADMA) was reported by Cantor Fitzgerald on August 10, 2023. The analyst firm set a price target for $6.00 expecting ADMA to rise to within 12 months (a possible 70.94% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for ADMA Biologics (NASDAQ: ADMA) was provided by Cantor Fitzgerald, and ADMA Biologics maintained their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a maintained with a price target of $5.00 to $6.00. The current price ADMA Biologics (ADMA) is trading at is $3.51, which is out of the analyst’s predicted range.

The latest price target for ADMA Biologics (NASDAQ: ADMA) was reported by Cantor Fitzgerald on August 10, 2023. The analyst firm set a price target for $6.00 expecting ADMA to rise to within 12 months (a possible 70.94% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for ADMA Biologics (NASDAQ: ADMA) was provided by Cantor Fitzgerald, and ADMA Biologics maintained their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a maintained with a price target of $5.00 to $6.00. The current price ADMA Biologics (ADMA) is trading at is $3.51, which is out of the analyst’s predicted range.

The latest price target for ADMA Biologics (NASDAQ: ADMA) was reported by Cantor Fitzgerald on August 10, 2023. The analyst firm set a price target for $6.00 expecting ADMA to rise to within 12 months (a possible 70.94% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for ADMA Biologics (NASDAQ: ADMA) was provided by Cantor Fitzgerald, and ADMA Biologics maintained their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a maintained with a price target of $5.00 to $6.00. The current price ADMA Biologics (ADMA) is trading at is $3.51, which is out of the analyst’s predicted range.

The latest price target for ADMA Biologics (NASDAQ: ADMA) was reported by Cantor Fitzgerald on August 10, 2023. The analyst firm set a price target for $6.00 expecting ADMA to rise to within 12 months (a possible 70.94% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for ADMA Biologics (NASDAQ: ADMA) was provided by Cantor Fitzgerald, and ADMA Biologics maintained their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a maintained with a price target of $5.00 to $6.00. The current price ADMA Biologics (ADMA) is trading at is $3.51, which is out of the analyst’s predicted range.

The latest price target for ADMA Biologics (NASDAQ: ADMA) was reported by Cantor Fitzgerald on August 10, 2023. The analyst firm set a price target for $6.00 expecting ADMA to rise to within 12 months (a possible 70.94% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for ADMA Biologics (NASDAQ: ADMA) was provided by Cantor Fitzgerald, and ADMA Biologics maintained their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a maintained with a price target of $5.00 to $6.00. The current price ADMA Biologics (ADMA) is trading at is $3.51, which is out of the analyst’s predicted range.

The latest price target for ADMA Biologics (NASDAQ: ADMA) was reported by Cantor Fitzgerald on August 10, 2023. The analyst firm set a price target for $6.00 expecting ADMA to rise to within 12 months (a possible 70.94% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for ADMA Biologics (NASDAQ: ADMA) was provided by Cantor Fitzgerald, and ADMA Biologics maintained their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a maintained with a price target of $5.00 to $6.00. The current price ADMA Biologics (ADMA) is trading at is $3.51, which is out of the analyst’s predicted range.

The latest price target for ADMA Biologics (NASDAQ: ADMA) was reported by Cantor Fitzgerald on August 10, 2023. The analyst firm set a price target for $6.00 expecting ADMA to rise to within 12 months (a possible 70.94% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for ADMA Biologics (NASDAQ: ADMA) was provided by Cantor Fitzgerald, and ADMA Biologics maintained their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a maintained with a price target of $5.00 to $6.00. The current price ADMA Biologics (ADMA) is trading at is $3.51, which is out of the analyst’s predicted range.

The latest price target for ADMA Biologics (NASDAQ: ADMA) was reported by Cantor Fitzgerald on August 10, 2023. The analyst firm set a price target for $6.00 expecting ADMA to rise to within 12 months (a possible 70.94% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for ADMA Biologics (NASDAQ: ADMA) was provided by Cantor Fitzgerald, and ADMA Biologics maintained their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a maintained with a price target of $5.00 to $6.00. The current price ADMA Biologics (ADMA) is trading at is $3.51, which is out of the analyst’s predicted range.